ActivBiotics

31 articles about ActivBiotics

• ActivBiotics Assignee Issues First Distribution of Cash to Creditors

  6/20/2008

• ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million

  4/3/2008

• ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million

  4/2/2008

• ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer

  3/6/2008

• ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates, on March 14, 2008

  3/5/2008

• ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics

  2/25/2008

• ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD

  2/19/2008

• ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication

  2/5/2008

• ActivBiotics Completes Sale of Fixed Assets

  1/29/2008

• ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Candidates

  1/28/2008

• ActivBiotics Extends Deadline to March 14, 2008 for the Sale of Proprietary Assets, Including Drug Product Candidates

  1/15/2008

• ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates

  12/19/2007

• ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease

  10/24/2007

• ActivBiotics Appoints Steven C. Gilman Chairman and CEO

  5/1/2007

• ActivBiotics Announces Initiation Of Phase II Study In Carotid Atherosclerosis

  2/14/2007

• The Day In Review: ActivBiotics And Thermage, Inc. Lower IPO Range

  11/9/2006

• ActivBiotics Cuts IPO Price To $8-$10 Per Share

  11/9/2006

• IPO Watch: ActivBiotics Targets Bacterial Diseases/Inflammation

  11/8/2006

• ActivBiotics Sets IPO At 4 Million Shares, $12-$14

  10/23/2006

• ActivBiotics Announces Completion Of Patient Enrollment In Phase III Clinical Trial In Peripheral Arterial Disease

  9/26/2006